Skip to main content

Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease

  • Chapter
Data Monitoring in Clinical Trials

Abstract

This trial was undertaken to test the hypothesis that two-drug initial therapy for acute graft-versus-host disease (GVHD) would produce better control of GVHD and less exposure to corticosteroids than the standard treatment of corticosteroids alone. All participants had undergone allogeneic hematopoietic stem cell transplantation (HSCT) and developed acute GVHD. Subjects were randomized to treatment with corticosteroids plus placebo or corticosteroids plus daclizumab. The trial was continued past its first interim analysis (~30%; evaluable subjects) but was stopped after the second interim analysis (~50%; evaluable subjects) when the two-drug arm was associated with worse overall survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, et al. 1990. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75:1024–1030.

    Google Scholar 

  2. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al. 1998. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968.

    Article  Google Scholar 

  3. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. 1990. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76:1464–1472.

    Google Scholar 

  4. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. 2002. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 8:387–394.

    Article  Google Scholar 

  5. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1995. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825–828.

    Google Scholar 

  6. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD, Edwards N, Mancini DM. 2000. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody [comment]. N Engl J Med 342:613–619.

    Article  Google Scholar 

  7. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F. Phase III Daclizumab Study Group. 2001. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 72:839–845.

    Article  Google Scholar 

  8. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. 2003. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326:789.

    Article  Google Scholar 

  9. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, et al. 2000. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95:83–89.

    Google Scholar 

  10. O’Brien PC, Fleming TR. 1979. A multiple testing procedure for clinical trials. Biometrics 35:549–556.

    Article  Google Scholar 

  11. Jennison C, Turnbull BW. 1989. The repeated confidence interval approach. J Royal Stat Soc 51:305–334.

    MathSciNet  MATH  Google Scholar 

  12. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL Jr, et al. 2004. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: Results of a randomized trial. Blood 104:1559–1564.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Zahrieh, D., Lee, S.J., Harrington, D. (2006). Data Monitoring of a Placebo-Controlled Trial of Daclizumab in Acute Graft-Versus-Host Disease. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_25

Download citation

Publish with us

Policies and ethics